24 research outputs found
Oleanolic acid: a novel cardioprotective agent that blunts hyperglycemia-induced contractile dysfunction
Diabetes constitutes a major health challenge. Since cardiovascular complications are common in diabetic patients this will further increase the overall burden of disease. Furthermore, stress-induced hyperglycemia in non-diabetic patients with acute myocardial infarction is associated with higher in-hospital mortality. Previous studies implicate oxidative stress, excessive flux through the hexosamine biosynthetic pathway (HBP) and a dysfunctional ubiquitin-proteasome system (UPS) as potential mediators of this process. Since oleanolic acid (OA; a clove extract) possesses antioxidant properties, we hypothesized that it attenuates acute and chronic hyperglycemia-mediated pathophysiologic molecular events (oxidative stress, apoptosis, HBP, UPS) and thereby improves contractile function in response to ischemia-reperfusion. We employed several experimental systems: 1) H9c2 cardiac myoblasts were exposed to 33 mM glucose for 48 hr vs. controls (5 mM glucose); and subsequently treated with two OA doses (20 and 50 µM) for 6 and 24 hr, respectively; 2) Isolated rat hearts were perfused ex vivo with Krebs-Henseleit buffer containing 33 mM glucose vs. controls (11 mM glucose) for 60 min, followed by 20 min global ischemia and 60 min reperfusion ± OA treatment; 3) In vivo coronary ligations were performed on streptozotocin treated rats ± OA administration during reperfusion; and 4) Effects of long-term OA treatment (2 weeks) on heart function was assessed in streptozotocin-treated rats. Our data demonstrate that OA treatment blunted high glucose-induced oxidative stress and apoptosis in heart cells. OA therapy also resulted in cardioprotection, i.e. for ex vivo and in vivo rat hearts exposed to ischemia-reperfusion under hyperglycemic conditions. In parallel, we found decreased oxidative stress, apoptosis, HBP flux and proteasomal activity following ischemia-reperfusion. Long-term OA treatment also improved heart function in streptozotocin-diabetic rats. These findings are promising since it may eventually result in novel therapeutic interventions to treat acute hyperglycemia (in non-diabetic patients) and diabetic patients with associated cardiovascular complications
Partial inhibition of the ubiquitin– proteasome system ameliorates cardiac dysfunction following ischemia–reperfusion in the presence of high glucose
Abstract
Background: Acute hyperglycemia co-presenting with myocardial infarction (in diabetic and non-diabetic individuals)
is often associated with a poor prognosis. Although acute hyperglycemia induces oxidative stress that can lead to
dysregulation of the ubiquitin–proteasome system (UPS), it is unclear whether increased/decreased UPS is detrimental
with ischemia–reperfusion under such conditions. As our earlier data implicated the UPS in cardiac damage, we
hypothesized that its inhibition results in cardioprotection with ischemia–reperfusion performed under conditions
that simulate acute hyperglycemia.
Methods: Ex vivo rat heart perfusions were performed with Krebs–Henseleit buffer containing 33 mM glucose vs.
controls (11 mM glucose) for 60 min stabilization, followed by 20 min global ischemia and 60 min reperfusion ± 5 µM
lactacystin and 10 µM MG-132, respectively. The UPS inhibitors were added during the first 20 min of the reperfusion
phase and various cardiac functional parameters evaluated. In parallel experiments, infarct sizes were assessed
following 20 min regional ischemia and 120 min reperfusion ± each of the respective UPS inhibitors (added during
reperfusion). Heart tissues were collected and analyzed for markers of oxidative stress, UPS activation, inflammation
and autophagy.
Results: The proteasome inhibitor doses and treatment duration here employed resulted in partial UPS inhibition
during the reperfusion phase. Both lactacystin and MG-132 administration resulted in cardioprotection in our
experimental system, with MG-132 showing a greater effect. The proteasome inhibitors also enhanced cardiac
superoxide dismutase protein levels (SOD1, SOD2), attenuated pro-inflammatory effects and caused an upregulation
of autophagic markers.
Conclusions: This study established that partial proteasome inhibition elicits cardioprotection in hearts exposed
to ischemia–reperfusion with acute simulated hyperglycemia. These data reveal that protease inhibition triggered
three major protective effects, i.e. (a) enhancing myocardial anti-oxidant defenses, (b) attenuating inflammation, and
(c) increasing the autophagic response. Thus the UPS emerges as a unique therapeutic target for the treatment of
ischemic heart disease under such conditions.
Keywords: Ubiquitin–proteasome system, Ischemia–reperfusion, Cardiac dysfunction, Hyperglycemia, Inflammation,
Oxidative stress, Autophagyhttp://www.cardiab.com/Background:
Acute hyperglycemia co-presenting with myocardial infarction (in diabetic and non-diabetic individu-
als) is often associated with a poor prognosis. Although acute hyperglycemia induces oxidative stress that can lead to
dysregulation of the ubiquitin–proteasome system (UPS), it is unclear whether increased/decreased UPS is detrimen-
tal with ischemia–reperfusion under such conditions. As our earlier data implicated the UPS in cardiac damage, we
hypothesized that its inhibition results in cardioprotection with ischemia–reperfusion performed under conditions
that simulate acute hyperglycemia.
Methods:
Ex vivo rat heart perfusions were performed with Krebs–Henseleit buffer containing 33 mM glucose vs. controls (11 mM glucose) for 60 min stabilization, followed by 20 min global ischemia and 60 min reperfusion ± 5 μM lactacystin and 10
μM MG-132, respectively. The UPS inhibitors were added during the first 20 min of the reperfusion phase and various cardiac functional parameters evaluated. In parallel experiments, infarct sizes were assessed following 20 min regional ischemia and 120 min reperfusion ± each of the respective UPS inhibitors (added during reperfusion). Heart tissues were collected and analyzed for markers of oxidative stress, UPS activation, inflammation and autophagy.
Results:
The proteasome inhibitor doses and treatment duration here employed resulted in partial UPS inhibi-
tion during the reperfusion phase. Both lactacystin and MG-132 administration resulted in cardioprotection in our
experimental system, with MG-132 showing a greater effect. The proteasome inhibitors also enhanced cardiac
superoxide dismutase protein levels (SOD1, SOD2), attenuated pro-inflammatory effects and caused an upregulation
of autophagic markers.
Conclusions:
This study established that partial proteasome inhibition elicits cardioprotection in hearts exposed
to ischemia–reperfusion with acute simulated hyperglycemia. These data reveal that protease inhibition triggered
three major protective effects, i.e. (a) enhancing myocardial anti-oxidant defenses, (b) attenuating inflammation, and
(c) increasing the autophagic response. Thus the UPS emerges as a unique therapeutic target for the treatment of
ischemic heart disease under such condition
Resveratrol Co-Treatment Attenuates the Effects of HIV Protease Inhibitors on Rat Body Weight and Enhances Cardiac Mitochondrial Respiration
<div><p>Since the early 1990s human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) emerged as a global health pandemic, with sub-Saharan Africa the hardest hit. While the successful roll-out of antiretroviral (ARV) therapy provided significant relief to HIV-positive individuals, such treatment can also elicit damaging side-effects. Here especially HIV protease inhibitors (PIs) are implicated in the onset of cardio-metabolic complications such as type-2 diabetes and coronary heart disease. As there is a paucity of data regarding suitable co-treatments within this context, this preclinical study investigated whether resveratrol (RSV), aspirin (ASP) or vitamin C (VitC) co-treatment is able to blunt side-effects in a rat model of chronic PI exposure (Lopinavir/Ritonavir treatment for 4 months). Body weights and weight gain, blood metabolite levels (total cholesterol, HDL, LDL, triglycerides), echocardiography and cardiac mitochondrial respiration were assessed in PI-treated rats ± various co-treatments. Our data reveal that PI treatment significantly lowered body weight and cardiac respiratory function while no significant changes were found for heart function and blood metabolite levels. Moreover, all co-treatments ameliorated the PI-induced decrease in body weight after 4 months of PI treatment, while RSV co-treatment enhanced cardiac mitochondrial respiratory capacity in PI-treated rats. This pilot study therefore provides novel hypotheses regarding RSV co-treatment that should be further assessed in greater detail.</p></div
Left Ventricular Parameters as Measured with Echocardiography after 4 Months of Treatment.
<p>Left Ventricular Parameters as Measured with Echocardiography after 4 Months of Treatment.</p
Morphometric Changes following 4 Months of Treatment.
<p>Morphometric Changes following 4 Months of Treatment.</p
Blood Metabolite Levels following 4 Months of Treatment.
<p>Blood Metabolite Levels following 4 Months of Treatment.</p
Muscle ring finger-3 protects against diabetic cardiomyopathy induced by a high fat diet
CITATION: Quintata, M. T. et al. 2015. Muscle ring finger-3 protects against diabetic cardiomyopathy induced by a high fat diet. BMC Endocrine Disorders, 15:36, doi:10.1186/s12902-015-0028-z.The original publication is available at http://bmcendocrdisord.biomedcentral.comBackground: The pathogenesis of diabetic cardiomyopathy (DCM) involves the enhanced activation of peroxisome
proliferator activating receptor (PPAR) transcription factors, including the most prominent isoform in the heart,
PPARα. In cancer cells and adipocytes, post-translational modification of PPARs have been identified, including
ligand-dependent degradation of PPARs by specific ubiquitin ligases. However, the regulation of PPARs in
cardiomyocytes and heart have not previously been identified. We recently identified that muscle ring finger-1
(MuRF1) and MuRF2 differentially inhibit PPAR activities by mono-ubiquitination, leading to the hypothesis that
MuRF3 may regulate PPAR activity in vivo to regulate DCM.
Methods: MuRF3−/− mice were challenged with 26 weeks 60 % high fat diet to induce insulin resistance and DCM.
Conscious echocardiography, blood glucose, tissue triglyceride, glycogen levels, immunoblot analysis of intracellular
signaling, heart and skeletal muscle morphometrics, and PPARα, PPARβ, and PPARγ1 activities were assayed.
Results: MuRF3−/− mice exhibited a premature systolic heart failure by 6 weeks high fat diet (vs. 12 weeks in
MuRF3+/+). MuRF3−/− mice weighed significantly less than sibling-matched wildtype mice after 26 weeks HFD. These
differences may be largely due to resistance to fat accumulation, as MRI analysis revealed MuRF3−/− mice had
significantly less fat mass, but not lean body mass. In vitro ubiquitination assays identified MuRF3 mono-ubiquitinated
PPARα and PPARγ1, but not PPARβ.
Conclusions: These findings suggest that MuRF3 helps stabilize cardiac PPARα and PPARγ1 in vivo to support
resistance to the development of DCM.
MuRF3 also plays an unexpected role in regulating fat storage despite being found only in striated muscle.http://bmcendocrdisord.biomedcentral.com/articles/10.1186/s12902-015-0028-zPublisher's versio
Diminished apoptosis in OA-treated H9c2 cells (flow cytometry).
<p>Flow cytometric analysis using the Annexin V/FITC apoptosis assay kit to evaluate the effects of 100 µM OA treatment under control and high glucose culturing conditions (24 hr). (A), (B), (C) and (D) Representative FACS analyses of four individual experiments corresponding to control and high glucose ± OA treatment, respectively. (E) and (F) Quantification of OA treatment after 6 and 24 hr, respectively. Values are normalized to the control and expressed as mean ± SEM (n = 4). ***p<0.001 vs. controls and ##, ### p<0.01, p<0.001 vs. high glucose exposure without OA treatment.</p
Long-term OA treatment improves cardiac function in STZ-diabetic rats.
<p>Sprague-Dawley rats were injected with STZ and followed for a 2-week period ± daily OA treatment. Subsequently, isolated hearts from STZ-diabetic and matched controls were perfused and action potentials recorded via a force transducer. Values are expressed as mean ± SEM (n = 6). <b>**</b>p<0.05 vs. non-diabetic control and ***p<0.01 vs. respective controls.</p